NASDAQ:XTLB XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free XTLB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.35▼$2.4950-Day Range$3.43▼$5.2052-Week Range$1.73▼$6.69Volume6,198 shsAverage Volume112,627 shsMarket Capitalization$13.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsEarningsHeadlinesShort InterestSocial MediaStock AnalysisCompetitorsEarningsHeadlinesShort InterestSocial Media Get XTL Biopharmaceuticals alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About XTL BiopharmaceuticalsXTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.Read More Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy XTLB Stock News HeadlinesApril 26, 2024 | wsj.comXTL Biopharmaceuticals Ltd. ADRMarch 20, 2024 | msn.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%April 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 20, 2024 | msn.comUS Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top ViewsMarch 20, 2024 | markets.businessinsider.comDow Surges 350 Points; Fed Holds Rates SteadyMarch 20, 2024 | markets.businessinsider.comCrude Oil Surges 2%; Signet Jewelers Shares Spike HigherMarch 20, 2024 | globenewswire.comXTL To Aquire The Social ProxyFebruary 17, 2024 | investing.comXTL Biopharmaceuticals Ltd ADR (XTLB)April 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.October 23, 2023 | finance.yahoo.comXTL Biopharmaceuticals Ltd (H2K2.MU)October 23, 2023 | finanznachrichten.deXTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyOctober 21, 2023 | finanznachrichten.deXTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelOctober 20, 2023 | finance.yahoo.comXTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelOctober 20, 2023 | finance.yahoo.comXTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyOctober 1, 2022 | seekingalpha.comXTLB XTL Biopharmaceuticals Ltd.August 8, 2022 | reuters.comX T L Biopharmaceuticals LtdJuly 23, 2022 | seekingalpha.comLIFE, TBLT and XTLB among pre market gainersDecember 15, 2021 | uk.finance.yahoo.comXTL Biopharmaceuticals Ltd. (XTLB)See More Headlines Receive XTLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XTLB CUSIPN/A CIK1023549 Webwww.xtlbio.com Phone(729) 955-7080Fax972-3611-6605EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.05% Return on Assets-68.83% Debt Debt-to-Equity RatioN/A Current Ratio14.09 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book3.29Miscellaneous Outstanding Shares5,450,000Free Float3,869,000Market Cap$13.08 million OptionableNot Optionable Beta1.21 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesShlomo Spokone ShalevChief Executive Officer & Executive DirectorItay WeinsteinChief Financial OfficerDaphna ParanMedical DirectorKey CompetitorsTraws PharmaNASDAQ:TRAWABVC BioPharmaNASDAQ:ABVCEdesa BiotechNASDAQ:EDSANanoViricidesNYSE:NNVCNeuroBo PharmaceuticalsNASDAQ:NRBOView All Competitors XTLB Stock Analysis - Frequently Asked Questions Are investors shorting XTL Biopharmaceuticals? XTL Biopharmaceuticals saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 60,200 shares, a drop of 86.2% from the March 31st total of 437,200 shares. Based on an average trading volume of 726,100 shares, the days-to-cover ratio is currently 0.1 days. View XTL Biopharmaceuticals' Short Interest. When is XTL Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our XTLB earnings forecast. When did XTL Biopharmaceuticals' stock split? Shares of XTL Biopharmaceuticals reverse split on Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of XTL Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other XTL Biopharmaceuticals investors own include Sorrento Therapeutics (SRNE), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Akari Therapeutics (AKTX), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Gilead Sciences (GILD), Novus Therapeutics (NVUS) and Regulus Therapeutics (RGLS). This page (NASDAQ:XTLB) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
